Phaseline

Companies › Hangzhou Polymed Biopharmaceuticals

Hangzhou Polymed Biopharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
HPB-092
FLT3 and IRAK4 inhibitor
FLT3, IRAK4Phase 1Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)Jun 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT07137637HPB-092Phase 1Relapsed and Refractory Acute Myeloid Leukemia (RR-AML)OncologyJun 2027

Targets

FLT3 (1) IRAK4 (1)

Companies with the same targets

Daiichi Sankyo Sunshine Lake Pharma Ryvu Therapeutics Bristol-Myers Squibb Novartis Cullinan Therapeutics Aptose Biosciences Etnova Therapeutics Swedish Orphan Biovitrum Theradex

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.